Skip to main content

Table 1 Clinical characteristics: the high VDJ% group includes more patients with ASCT than with conventional chemotherapy

From: In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival

  Untreated/ Chemo RR/Chemo Untreated/ASCT RR/ASCT
High VDJ% 16 24 28 1
Low VDJ% 24 25 21 0
Total 40 49 49 1
  1. VDJ% in patients whose BM aspirates were taken at diagnosis or relapse and who ultimately received either conventional chemotherapy or ASCT.